GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Regencell Bioscience
The shares of Regencell Bioscience, a biotech company focused on traditional Chinese medicine, are highly volatile. Their price is not driven by revenue but rather reflects investors' speculative expectations regarding the clinical trial results of their drugs.
Share prices of companies in the market segment - Neuro
Regencell Bioscience operates in the biotechnology segment, researching traditional Chinese medicines. We classify it as part of the Neurological Pharmaceuticals sector. The chart below reflects the dynamics of this entire innovative, yet highly speculative, segment.
Broad Market Index - GURU.Markets
Regencell Bioscience is a biopharmaceutical company developing traditional Chinese medicine-based drugs for the treatment of neurological disorders. It is a component of the GURU.Markets index, and the chart below shows how its stock compares to the broader market.
Change in the price of a company, segment, and market as a whole per day
RGC - Daily change in the company's share price Regencell Bioscience
Regencell Bioscience shares, which operate in the traditional Chinese medicine niche, are extremely volatile due to their speculative nature and low liquidity. Daily price changes directly reflect this sensitivity. This metric is important for risk analysis in niche biotech companies on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Neuro
Regencell Bioscience Holdings Limited is a biotechnology company. This chart highlights the extreme volatility of the sector. Comparing this to RGC's performance, which depends on the results of its clinical trials, helps assess it as a high-risk asset compared to more diversified companies.
Daily change in the price of a broad market stock, index - GURU.Markets
Regencell Bioscience is a biopharmaceutical company developing traditional Chinese medicine-based drugs for the treatment of neurological disorders. This is a highly speculative and innovative field. The chart below illustrates the high volatility typical of the biotech sector.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Regencell Bioscience
Regencell is a biotech company working on treatments for neurological diseases. Its shares represent a venture capital bet on scientific success. Their high volatility, driven by expectations, contributes to the complex and multifaceted dynamics of the entire stock market.
Annual dynamics of market capitalization of the market segment - Neuro
Regencell Bioscience is a biotechnology company developing drugs based on traditional Chinese medicine for the treatment of neurological disorders. Its approach is unconventional for the Western market. Its stock price is extremely volatile, reflecting the high risks and speculative interest in its unique research.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Regencell Bioscience is an early-stage biotech company whose value reflects hopes for future scientific breakthroughs. Its shares exhibit extreme volatility and are completely disconnected from economic cycles. The company's chart isn't about business, but about binary events: the success or failure of clinical trials.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Regencell Bioscience
Regencell, a biopharmaceutical company, is extremely volatile and speculative in price. Monthly fluctuations on the chart reflect not operating cycles, but rather news about the progress of its research into neurological disorders, which is crucial to its future value.
Monthly dynamics of market capitalization of the market segment - Neuro
Regencell is a biotech company focused on neuroscience. Its value is based on the potential of its scientific developments. Monthly fluctuations reflect progress in clinical trials and funding announcements.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Regencell Bioscience is a biopharmaceutical company specializing in the development of traditional Chinese medicine-based drugs for the treatment of neurological disorders. The chart below shows the overall market sentiment. Regencell's performance is determined almost exclusively by clinical trial results and regulatory decisions.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Regencell Bioscience
Shares of Regencell Bioscience, a company active in the alternative medicine sector, are extremely sensitive to news. Weekly performance almost always reflects the publication of research results, regulatory announcements, and any reports of progress in the treatment of neurological disorders.
Weekly dynamics of market capitalization of the market segment - Neuro
Regencell Bioscience operates in the highly speculative early-stage biotech sector, where investor sentiment drives broad trends. Any major success or failure in the industry impacts everyone's risk appetite. The chart will show whether RGC is following the general flow of biotech speculation or whether its unique news is creating its own trend.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
As an early-stage biotech company, Regencell Bioscience often ignores broader market trends. Its fate depends not on GDP or inflation, but on clinical trial results. The chart below clearly demonstrates how RGC shares can rise or fall on their own news, while the overall market moves in a different direction.
Market capitalization of the company, segment and market as a whole
RGC - Market capitalization of the company Regencell Bioscience
Regencell Bioscience's market capitalization is a graph of hopes for the treatment of pediatric neurological disorders. It reflects not current earnings, but rather investors' faith in the potential of its research based on traditional Chinese medicine. Its high volatility reflects how the market assesses the risks and potential breakthroughs in this complex field.
RGC - Share of the company's market capitalization Regencell Bioscience within the market segment - Neuro
Regencell Bioscience is a biopharmaceutical company focused on traditional Chinese medicine (TCM) treatments for neurological disorders. Its market cap share in the niche segment reflects investors' faith in its unconventional approach. The chart below illustrates the high valuation volatility typical of early-stage biotech.
Market capitalization of the market segment - Neuro
Regencell Bioscience is researching treatments for neurodegenerative diseases using traditional Chinese medicine. The chart below shows the market capitalization of the neuroscience biotechnology niche. This represents a market with high risks but also enormous potential for breakthroughs.
Market capitalization of all companies included in a broad market index - GURU.Markets
Regencell Bioscience is a biotech company specializing in traditional Chinese medicine (TCM) treatments for neurological disorders. Its market cap reflects investors' bet on integrating alternative approaches into modern medicine. Its tiny global market share highlights the growth potential of niche therapies.
Book value capitalization of the company, segment and market as a whole
RGC - Book value capitalization of the company Regencell Bioscience
Regencell's book value is primarily intellectual and financial capital. It consists of patents for treatment methods, cash allocated for clinical trials, and laboratory assets. The chart below shows how the company accumulates resources to advance its scientific research from concept to potential drug.
RGC - Share of the company's book capitalization Regencell Bioscience within the market segment - Neuro
Regencell Bioscience, a bioscience company, relies on specialized laboratories for its research. These research facilities are its key tangible asset. The chart shows how its share of physical infrastructure compares to other companies in the innovative healthcare sector.
Market segment balance sheet capitalization - Neuro
Below you can see the overall book value of the pharmaceutical sector. Against this backdrop, Regencell Bioscience, which specializes in traditional Chinese medicine, appears like a lightweight R&D company. Its value lies in its formulas and research, not large manufacturing plants, making its business non-capital-intensive at this stage.
Book value of all companies included in the broad market index - GURU.Markets
Regencell Bioscience is a biotech company whose primary assets are not buildings, but patents and clinical research data in neuroscience. Their balance sheet represents the value of hope and scientific progress. Against the backdrop of the material world depicted in the chart, Regencell illustrates how intellectual capital can change people's lives.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Regencell Bioscience
Regencell's book value is its cash and research. Its market capitalization is a bet on the success of its approach to treating neurological disorders using traditional Chinese medicine. The MvsBCap_Co chart reflects the vast gap between its modest assets and its high hopes.
Market to book capitalization ratio in a market segment - Neuro
Regencell Bioscience is a biotech company operating in the traditional Chinese medicine niche for the treatment of neurological disorders. The chart shows the high speculative market valuation of its potential developments, which is many times higher than its current tangible assets.
Market to book capitalization ratio for the market as a whole
Regencell Bioscience is engaged in research and development of treatments for neurodegenerative diseases and autism spectrum disorders based on traditional Chinese medicine. The company's core value lies in its intellectual property and the potential for future discoveries. This chart illustrates why biotech companies can achieve high valuations even with minimal tangible assets.
Debts of the company, segment and market as a whole
RGC - Company debts Regencell Bioscience
For biotech company Regencell Bioscience, debt policy is closely tied to funding research and clinical trials. This chart reflects capital raising for the development of treatments for neurological disorders. In this sector, debt is a risky but necessary investment in potential scientific breakthroughs and the development of new drugs.
Market segment debts - Neuro
Regencell Bioscience is a biotech company focused on traditional Chinese medicine (TCM) treatments for neurological disorders. Clinical trials in this area require time and capital. This chart reflects the young biotech's financial strategy: how much it relies on external funding to advance its research.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Regencell Bioscience
Regencell Bioscience is an early-stage biotech company focused on treating neurological disorders. This chart shows the startup's financial position in R&D. A near-absence of debt and reliance on equity is typical for such companies, as their future depends on the success of clinical trials rather than current revenue.
Market segment debt to market segment book capitalization - Neuro
Regencell Bioscience is a biotech company focused on drugs for neurological disorders. The chart shows debt trends in this highly specialized segment. For a research-stage company, this is a key indicator: whether it relies on equity or debt to fund development, and how this compares to the industry.
Debt to book value of all companies in the market
Regencell Bioscience is an early-stage biotech company. The chart shows the overall market leverage. For a company reliant on equity financing, it provides context: how investor appetite for risky biotech startups depends on the overall market conditions and the availability of capital in the economy.
P/E of the company, segment and market as a whole
P/E - Regencell Bioscience
This chart for Regencell Bioscience, an early-stage biopharmaceutical company, is a measure of hope, not profit. A frequently negative or extremely high P/E indicates that investors are betting on the success of its research into treating neurological disorders. The ratio's dynamics depend entirely on news about clinical trials and potential breakthroughs.
P/E of the market segment - Neuro
This chart shows the average valuation for early-stage biopharmaceutical companies. Firms like Regencell typically don't have a P/E ratio. However, this metric provides context, showing the overall level of investor interest in the sector. It helps understand whether the biotech sector is in a bullish or depressed phase.
P/E of the market as a whole
Regencell Bioscience is a biotech company focused on traditional Chinese medicine (TCM) treatments for neurological disorders. Its valuation is almost entirely dependent on clinical trial results. Compared to this chart, which shows the average valuation of mature companies, Regencell looks like a venture-backed bet on a scientific breakthrough, operating outside the general market rules.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Regencell Bioscience
Regencell Bioscience is a biotechnology company focused on research into traditional Chinese medicine for the treatment of neurological disorders. The company's future depends entirely on clinical trial results and regulatory approval. This chart demonstrates an extremely high degree of speculative expectation based on faith in a potential scientific breakthrough.
%20P%2FE%20Regencell%20Bioscience&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Regencell-Bioscience&v=1772582220698 "Chart of the company's future (projected) P/E Regencell Bioscience")
Future (projected) P/E of the market segment - Neuro
Regencell Bioscience is a biotech company focused on research into treating neurological disorders using traditional Chinese medicine. This is a highly specialized and high-risk niche. The chart reflects expectations for the biotech sector, providing context for assessing how the market views these unconventional approaches to medicine.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Neuro&v=1772582220753 "Future (projected) P/E graph of the market segment - Neuro")
Future (projected) P/E of the market as a whole
Regencell Bioscience is a biotech company focused on traditional Chinese medicine (TCM) treatments for neurological disorders. For an early-stage company, the overall market backdrop, as seen in the chart, is critical. High optimism and risk appetite facilitate the company's ability to attract investment to conduct clinical trials and bring its alternative treatments to market.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772582220845 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Regencell Bioscience
Regencell Bioscience develops traditional Chinese medicine-based treatments for neurodegenerative diseases and autism spectrum disorders. This chart shows the biotech startup's financial performance. During the research and clinical trials phase, profits are likely to be negative, and the trend reflects R&D expenses.
Profit of companies in the market segment - Neuro
Regencell Bioscience is a biotech company focused on traditional Chinese medicine (TCM) treatments for neurological disorders. Profitability in this niche is highly volatile and depends on the success of clinical trials. This chart reflects the state of highly specialized biotech, where the potential for breakthroughs is coupled with a high risk of failure.
Overall market profit
Regencell Bioscience is a biotech company specializing in traditional Chinese medicine (TCM) treatments for neurological disorders. Being in the early stages of development, its value is determined by its research potential rather than current cash flows. It is an example of a company whose trajectory is currently unaffected by general economic cycles.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Regencell Bioscience
Regencell Bioscience is a biotech company focused on research into traditional Chinese medicine for the treatment of neurological disorders. For such an early-stage company, revenue projections are a very distant prospect. This chart reflects analysts' speculative expectations regarding the success of clinical trials and the potential commercialization of its approaches.
%20profit%20of%20the%20company%20Regencell%20Bioscience&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Regencell-Bioscience&v=1772582221229 "Graph of future (projected) profit of the company Regencell Bioscience")
Future (predicted) profit of companies in the market segment - Neuro
Regencell Bioscience develops traditional Chinese medicine (TCM) treatments for neurological disorders such as autism and ADHD. The company works at the intersection of ancient practices and modern research. This chart shows forecasts for the biotech sector, reflecting investors' overall belief in the potential of alternative approaches to medicine.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Neuro&v=1772582221291 "Graph of future (predicted) profits of companies in a market segment - Neuro")
Future (predicted) profit of the market as a whole
Regencell Bioscience is an early-stage biotech company working in the field of traditional Chinese medicine. Unlike mature companies, its value depends not on current economic cycles, but on investors' faith in the future success of its developments. However, a positive overall outlook, as shown in this chart, creates risk appetite and facilitates capital raising for such innovative startups.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772582221297 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Regencell Bioscience
Regencell Bioscience is a biotech company specializing in the development of traditional Chinese medicine (TCM) treatments for neurological disorders. The company is in its early stages, and its revenue is minimal. The chart reflects speculative investor expectations, which are not based on current sales, but rather on potential breakthroughs in the treatment of complex diseases.
P/S market segment - Neuro
Regencell Bioscience is an early-stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases and autism spectrum disorders using traditional Chinese medicine. This chart reflects investor expectations for biotech companies, providing insight into the market's confidence in Regencell's unique approach.
P/S of the market as a whole
Regencell Bioscience develops traditional Chinese medicine drugs for the treatment of neurological disorders. It is an early-stage company with high risk and potential. This chart, showing average market valuations, clearly demonstrates the gap between the valuations of mature companies and speculative bets on biotech breakthroughs.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Regencell Bioscience
Regencell Bioscience is a biotechnology company focused on developing traditional Chinese medicine (TCM) treatments for neurological disorders. This chart reflects investors' confidence in the future commercial success of its developments. The valuation is based on expectations of positive clinical trial results and potential future sales.
%20P%2FS%20Regencell%20Bioscience&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Regencell-Bioscience&v=1772582221556 "The graph of the company's future (projected) P/S Regencell Bioscience")
Future (projected) P/S of the market segment - Neuro
Regencell Bioscience develops treatments based on traditional Chinese medicine for children with neurological disorders. This chart reflects investor expectations for the company's future revenue. For a young biotech company, it indicates the market's level of confidence in its scientific developments and their commercialization potential.
%20P%2FS%20market%20segment%20graph%20-%20Neuro&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Neuro&v=1772582221611 "Future (projected) P/S market segment graph - Neuro")
Future (projected) P/S of the market as a whole
Future revenue expectations may be linked to alternative approaches to medicine. Regencell Bioscience, focusing on research into traditional Chinese medicine for neurological disorders, represents a niche but interesting segment. Investor interest in such companies reflects the search for new sources of growth beyond traditional pharmaceuticals.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772582221626 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Regencell Bioscience
Regencell Bioscience is an early-stage biotechnology company focused on traditional Chinese medicine. Its current earnings curve reflects research and development rather than commercial sales. Future revenue growth will depend on the successful commercialization of its therapeutic approaches.
Sales of companies in the market segment - Neuro
Regencell Bioscience is a biopharmaceutical company focused on traditional Chinese medicine research for the treatment of neurological disorders, particularly ADHD and autism. This chart shows revenue in niche neuroscience segments, demonstrating the potential market size for alternative treatments that Regencell is targeting.
Overall market sales
Regencell Bioscience is a biotech company focused on research into traditional Chinese medicine for the treatment of neurological disorders. Being an early-stage company, its valuation depends on its research prospects and the investment climate. This general economic activity chart reflects investor appetite for risky but potentially breakthrough biotech startups.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Regencell Bioscience
Regencell Bioscience is a biotech company focused on developing traditional Chinese medicine (TCM) treatments for neurological disorders. Its future depends entirely on the success of clinical trials. The chart reflects highly speculative analyst forecasts, betting on a potential breakthrough in the treatment of these conditions.
%20sales%20of%20the%20company%20Regencell%20Bioscience&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Regencell-Bioscience&v=1772582221989 "Schedule of future (projected) sales of the company Regencell Bioscience")
Future (projected) sales of companies in the market segment - Neuro
Regencell Bioscience is a biotechnology company specializing in the development of traditional Chinese medicine (TCM) drugs for the treatment of neurological disorders. The company's success depends entirely on the results of clinical trials. This chart reflects forecasts for the entire neurological pharmaceutical segment, demonstrating analysts' overall expectations for the development of this medical field.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Neuro&v=1772582222022 "Schedule of future (projected) sales of companies in the market segment - Neuro")
Future (projected) sales of the market as a whole
Regencell Bioscience develops traditional Chinese medicine (TCM) treatments for neurological disorders. The company's future depends on successful clinical trials and market acceptance of its approaches. This chart reflects the overall economic climate, which impacts the availability of venture capital and investment in early-stage biotech startups.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772582222056 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Regencell Bioscience
Regencell Bioscience develops traditional Chinese medicine drugs for the treatment of neurological disorders. This chart reflects the financial aspects of its journey from research to market. It shows how close the company is to converting potential revenue into actual profit, a key challenge for any biotech company.
Market segment marginality - Neuro
Regencell Bioscience is an early-stage biopharmaceutical company focused on traditional Chinese medicine (TCM) treatments for neurological disorders. This chart shows its operating metrics relative to its industry, which, for a young company, indicates control over R&D costs as it moves toward commercialization.
Market marginality as a whole
Regencell Bioscience is an early-stage biotech company developing treatments for pediatric neurological disorders. Their valuation depends on the success of clinical trials, not on overall economic trends. However, this overall profitability curve impacts the availability of venture capital and investor willingness to fund risky projects.
Employees in the company, segment and market as a whole
Number of employees in the company Regencell Bioscience
Regencell Bioscience is a biopharmaceutical company focused on developing traditional Chinese medicine (TCM) treatments for neurological disorders. While in the research stage, the company has a small but highly qualified team. This chart shows the dynamics of the team of scientists and clinicians leading key developments.
Share of the company's employees Regencell Bioscience within the market segment - Neuro
Regencell Bioscience develops treatments based on traditional Chinese medicine for neurological disorders. This chart shows the concentration of unique specialists working at the intersection of traditional and modern science. The proportion of such experts within the company reflects its niche yet innovative approach to medicine.
Number of employees in the market segment - Neuro
Regencell Bioscience is an early-stage biotech company focused on drugs for the treatment of neurological disorders in children. This chart shows overall employment in biotech. For a startup like Regencell, it demonstrates the size of the talent pool from which to draw, but also the intense competition for specialized specialists from giants.
Number of employees in the market as a whole
Regencell Bioscience is an early-stage biotech company focused on traditional Chinese medicine (TCM) treatments for neurological disorders. The small staff seen in this chart is typical for R&D companies. Any change in headcount is a significant event, reflecting progress in clinical trials.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Regencell Bioscience (RGC)
Regencell Bioscience, an early-stage biotech, is a bet on the future. This chart shows that the company has virtually no physical assets or revenue, but the market highly values its scientific potential. The astronomical market capitalization per employee reflects the company's intellectual property and investors' hopes for a breakthrough.
%20of%20the%20company%20Regencell%20Bioscience%20(RGC)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Regencell-Bioscience-RGC&v=1772582222969 "Chart of market capitalization per employee (in thousands of dollars) of the company Regencell Bioscience (RGC)")
Market capitalization per employee (in thousands of dollars) in the market segment - Neuro
Regencell Bioscience is an early-stage biotech company focused on treating autism spectrum disorders. It's a speculative R&D company. Its market capitalization is based solely on faith in its science. This metric, compared to the industry average, reflects the market premium paid per scientist for this "ticket to the future."
%20by%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Neuro&v=1772582223177 "Market capitalization per employee (in thousands of dollars) by market segment - Neuro")
Market capitalization per employee (in thousands of dollars) for the overall market
Regencell Bioscience is a biotech company focused on neuroscience research using traditional Chinese medicine. Like most biopharma companies, its valuation is based on its research potential. The extremely high valuation per employee reflects investor expectations for clinical trial results, not current operating performance.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772582223320 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Regencell Bioscience (RGC)
Regencell Bioscience is an early-stage biotech company focused on treating autism spectrum disorders (ASD) and ADHD using traditional Chinese medicine. This chart for such companies often shows a loss per employee, reflecting the intensive research and development (R&D) phase before commercial revenue is realized.
%20Chart%20Regencell%20Bioscience%20(RGC)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Regencell-Bioscience-RGC&v=1772582223358 "Company Profit Per Employee (in thousands of dollars) Chart Regencell Bioscience (RGC)")
Profit per employee (in thousands of dollars) in the market segment - Neuro
Regencell is an early-stage biotech company focused on treating neurodegenerative diseases (ADHD, autism) using traditional Chinese medicine. The company is unprofitable. This negative graph reflects the R&D budget burn. Every employee is a scientist working on alternative therapies.
%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Neuro&v=1772582223507 "Chart of profit per employee (in thousands of dollars) in the market segment - Neuro")
Profit per employee (in thousands of dollars) for the market as a whole
Regencell Bioscience (RGC) is an early-stage biopharmaceutical company using traditional Chinese medicine to develop treatments for ADHD, autism, and infectious diseases. It's a high-risk biotech. This graph of average market returns per employee provides context: it shows the potential for profitability per person in the R&D sector if their developments are successful.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772582223583 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Regencell Bioscience (RGC)
For Regencell Bioscience, a company working in traditional Chinese medicine for the treatment of neurological disorders, this chart reflects the early stages of commercialization. Revenue per employee growth will be a key indicator of the success of its unique approach and the market demand for its products.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Regencell-Bioscience-RGC&v=1772582223621 "Sales chart per company employee Regencell Bioscience (RGC)")
Sales per employee in the market segment - Neuro
Regencell Bioscience is an early-stage biotech company focused on treating autism and ADHD using traditional Chinese medicine. This metric compares their revenue per employee to the industry average. Given the company's stage of development, this helps understand how productive the company is in its niche compared to other biotech companies.
Sales per employee for the market as a whole
Regencell Bioscience (RGC) is an early-stage biopharmaceutical company focused on traditional Chinese medicine. For a company in the R&D stage, this metric is typically very low or nonexistent. The emergence and growth of revenue per employee on this chart will be a key signal of the start of commercialization of their developments and the transition from research to actual sales.
Short shares by company, segment and market as a whole
Shares shorted by company Regencell Bioscience (RGC)
Regencell Bioscience is a highly speculative biotech company attempting to treat autism spectrum disorders and ADHD using traditional Chinese medicine (TCM) approaches. This chart shows a very high number of bets against the company, reflecting the market's high skepticism about its scientific foundation and chances of success in clinical trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Regencell-Bioscience-RGC&v=1772582223782 "Short Shares Chart for the Company Regencell Bioscience (RGC)")
Shares shorted by market segment - Neuro
Regencell Bioscience (RGC) is a biotech company focused on traditional Chinese medicine research for the treatment of neurological disorders such as ADHD. This chart shows the aggregate short interest in the biotech sector. The high level reflects the market's general skepticism toward small companies in early-stage research.
Shares shorted by the overall market
Regencell Bioscience (RGC) is a speculative biotech company focused on autism and ADHD. When Short_All rises sharply, it signals market panic and a flight to safety. This pessimism is absolutely toxic for cash-burning companies like RGC. In times of fear, investors are unwilling to fund long-term research.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Regencell Bioscience (RGC)
Regencell Bioscience is a Hong Kong-based speculative biotech company focused on neuroscience. The business carries a dual risk. When this *global* pessimism indicator rises, investors (1) flee emerging markets and (2) sell off unprofitable biotechs, fearing financing risks.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Regencell-Bioscience-RGC&v=1772582224076 "RSI 14 indicator chart for the company's stock Regencell Bioscience (RGC)")
RSI 14 Market Segment - Neuro
Regencell Bioscience is a biotech company focused on researching traditional Chinese medicine for the treatment of neurological disorders such as ADHD and autism. This chart measures the overall momentum in the speculative biotech sector specializing in neuroscience. It helps assess whether the entire segment is overheated by expectations.
RSI 14 for the overall market
Regencell Bioscience is a highly speculative company using traditional Chinese medicine (TCM) to treat neurological disorders. This segment is extremely niche and risky. This market sentiment chart is a matter of survival for RGC: only in moments of extreme euphoria are investors willing to consider such unconventional and unproven approaches.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast RGC (Regencell Bioscience)
Regencell Bioscience is a biotech company specializing in traditional Chinese medicine (TCM) research for the treatment of neurological disorders such as ADHD and autism. This chart shows the average 12-month target from analysts. It reflects their (highly speculative) assessment of the likelihood of success in their clinical trials.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-RGC-Regencell-Bioscience&v=1772582224389 "A chart showing analyst consensus forecasts for the expected stock price. RGC (Regencell Bioscience)")
The difference between the consensus estimate and the actual stock price RGC (Regencell Bioscience)
Regencell Bioscience (RGC) is a biotech company researching traditional Chinese medicine (TCM)-based treatments for autism spectrum disorders (ASD) and ADHD. This chart shows high speculative value. It measures the gap between the price and the consensus target, reflecting whether analysts believe in their unconventional scientific approach.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-RGC-Regencell-Bioscience&v=1772582224427 "A chart showing the difference between the consensus forecast and the actual stock price. RGC (Regencell Bioscience)")
Analyst consensus forecast for stock prices by market segment - Neuro
Regencell Bioscience is a Hong Kong-based biotech company focused on developing drugs (based on traditional Chinese medicine) for the treatment of ADHD and autism. This chart shows analysts' overall expectations for the neuroscience sector, reflecting whether experts believe breakthroughs in the treatment of complex brain disorders are possible.
Analysts' consensus forecast for the overall market share price
Regencell Bioscience (RGC) is a one-pronged biotech company trying to treat neurological disorders (ADHD, autism) using traditional Chinese medicine. Market expectations, as seen in this chart, represent their risk appetite. During a downturn (pessimism), investors flee any R&D projects, especially those so unconventional.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Regencell Bioscience
Regencell Bioscience is an early-stage biopharmaceutical company focused on developing treatments for autism (ASD) and ADHD using traditional Chinese medicine approaches. This chart is highly speculative. It does not reflect revenue but rather serves as an indicator of market confidence in their innovative scientific approach and clinical trial results.
AKIMA Market Segment Index - Neuro
Regencell is a biotech company focused on neuroscience and autism, using traditional Chinese medicine (TCM) to develop its formulas. This composite metric evaluates R&D. The chart shows the segment average. This benchmark: how does Regencell's non-traditional (TCM) and speculative R&D approach differentiate it from the average pharma company?
The AKIM Index for the overall market
Regencell is a Hong Kong-based biotech company focused on developing TCM-based treatments for autism spectrum disorders (ASD) and ADHD. It's a high-risk bet. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this speculative scientific story stacks up against the backdrop of overall economic trends.
